Next Article in Journal
Mechanisms and Therapeutic Implications of Cell Death Induction by Indole Compounds
Next Article in Special Issue
Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
Previous Article in Journal
Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications
Previous Article in Special Issue
Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133
Open AccessReview

Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines

Ludwig Institute for Cancer Research and Université catholique de Louvain, de Duve Institute, 74 av. Hippocrate, P.O. Box B1-7403, B-1200 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2011, 3(3), 2904-2954; https://doi.org/10.3390/cancers3032904
Received: 26 May 2011 / Revised: 1 July 2011 / Accepted: 7 July 2011 / Published: 18 July 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
Human tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies. View Full-Text
Keywords: anergy; immunosuppression; cancer vaccines; galectin; tumor-infiltrating lymphocytes anergy; immunosuppression; cancer vaccines; galectin; tumor-infiltrating lymphocytes
Show Figures

Graphical abstract

MDPI and ACS Style

Wieërs, G.; Demotte, N.; Godelaine, D.; Van der Bruggen, P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers 2011, 3, 2904-2954. https://doi.org/10.3390/cancers3032904

AMA Style

Wieërs G, Demotte N, Godelaine D, Van der Bruggen P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers. 2011; 3(3):2904-2954. https://doi.org/10.3390/cancers3032904

Chicago/Turabian Style

Wieërs, Grégoire; Demotte, Nathalie; Godelaine, Danièle; Van der Bruggen, Pierre. 2011. "Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines" Cancers 3, no. 3: 2904-2954. https://doi.org/10.3390/cancers3032904

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop